Table 1 Large randomized controlled trials investigating pharmacological or interventional treatment for stroke prevention after ICH
From: Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage
Trial name | Design | Allocation ratio | Study population | Est. sample size (n) | Location | Intervention | Est. primary completion date |
|---|---|---|---|---|---|---|---|
Pharmacological treatment | |||||||
 APACHE-AF (NCT02565693) | Open label | 1:1 | ICH and AF | 100 | Netherlands | Apixaban vs antiplatelets or none | January 2021 |
 ASPIRE (NCT03907046) | Quadruple-blind | 1:1 | Non-lobar ICH and AF | 700 | USA | Apixaban vs ASS 81 mg/d | April 2024 |
 NASPAF-ICH (NCT02998905) | PROBE | 1:1 | ICH and AF | 100 | Canada | NOAC vs ASS 81 mg/d | October 2019 |
 PRESTIGE-AF | Open label | 1:1 | ICH | 662 | Europe | NOAC vs antiplatelets or none | November 2022 |
 SoSTART (NCT03153150) | PROBE | 1:1 | ICH and AF | 800 | United Kingdom | OAC vs antiplatelets or none | July 2021 |
 STATICH (NCT03186729) | PROBE | 1:1 | ICH and AF or no AF | 500 | Scandinavia | OAC or antiplatelets vs none | June 2021 |
Left atrial appendage occlusion (LAAO) | |||||||
 A3ICH (NCT03243175) | PROBE | 1:1:1 | ICH and AF | 300 | France | Apixaban vs LAAO vs antiplatelets or none | December 2022 |
 Amulet IDE (NCT02879448) | Open label | 1:1 | High bleeding risk and AF | 1878 | Worldwide | Amulet LAAO vs WATCHMAN LAAO | February 2020 |
 ASAP-TOO (NCT02928497) | Open label | 2:1 | High bleeding risk and AF | 888 | Belgium, Denmark, USA | LAAO vs antiplatelets or none | December 2023 |
 CLOSURE-AF (NCT03463317) | Open label | 1:1 | High bleeding risk and AF | 1512 | Germany | LAAO vs active comparator (NOAK or VKA) | February 2021 |
 LAAOS III (NCT01561651) | Quadruple-blind | 1:1 | Cardiopulmonary bypass surgery and AF | 4812 | Canada | Surgical LAAO vs best medical treatment | November 2022 |
 PRAGUE-17 (NCT02426944) | Open label | 1:1 | History of bleeding and AF | 400 | Czech Republic | LAAO vs NOAK | May 2018 |
 STROKECLOSE (NCT02830152) | PROBE | 2:1 | ICH and AF | 750 | Sweden | LAAO vs best medical treatment | May 2022 |